Cookie Settings
We use cookies to provide the best possible website experience for you. This includes cookies that are technically required to ensure a proper functioning of the website, as well as cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for displaying personalized content. You are free to choose the categories you would like to permit. Please note that depending on your settings, the full functionality of the website may no longer be available. Further information can be found in our Privacy Statement and Cookie Statement.
Separation of human leukocyte-enriched buffy coat using CD45 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD45-FITC. |
Peripheral blood before separation | CD45 – cells |
CD45 MicroBeads, humanFigure 1Separation of human leukocyte-enriched buffy coat using CD45 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD45-FITC. | CD45 MicroBeads, humanFigure 1Separation of human leukocyte-enriched buffy coat using CD45 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD45-FITC. |
CD45 + cells | |
CD45 MicroBeads, humanFigure 1Separation of human leukocyte-enriched buffy coat using CD45 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD45-FITC. |
Enrichment of tumor cells from a mixture of PBMCs and cells of the breast cancer cell line SK-BR3 using CD45 MicroBeads. (A) Cell mixture before separation (7×106 PBMCs were spiked with 20,000 tumor cells) (B) Negative fraction with enriched breast cancer cells |
A): | B): |
Cell mixture before separation (7×10 6 PBMCs were spiked with 20,000 tumor cells) | |
CD45 MicroBeads, humanFigure 3Enrichment of tumor cells from a mixture of PBMCs and cells of the breast cancer cell line SK-BR3 using CD45 MicroBeads. (A) Cell mixture before separation (7×106 PBMCs were spiked with 20,000 tumor cells) (B) Negative fraction with enriched breast cancer cells | CD45 MicroBeads, humanFigure 3Enrichment of tumor cells from a mixture of PBMCs and cells of the breast cancer cell line SK-BR3 using CD45 MicroBeads. (A) Cell mixture before separation (7×106 PBMCs were spiked with 20,000 tumor cells) (B) Negative fraction with enriched breast cancer cells |
Separation of human leukocyte-enriched buffy coat using CD45 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD45-FITC. |
Peripheral blood before separation | CD45 – cells |
CD45 MicroBeads, humanFigure 1Separation of human leukocyte-enriched buffy coat using CD45 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD45-FITC. | CD45 MicroBeads, humanFigure 1Separation of human leukocyte-enriched buffy coat using CD45 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD45-FITC. |
CD45 + cells | |
CD45 MicroBeads, humanFigure 1Separation of human leukocyte-enriched buffy coat using CD45 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells are stained with CD45-FITC. |
Enrichment of tumor cells from a mixture of PBMCs and cells of the breast cancer cell line SK-BR3 using CD45 MicroBeads. (A) Cell mixture before separation (7×106 PBMCs were spiked with 20,000 tumor cells) (B) Negative fraction with enriched breast cancer cells |
A): | B): |
Cell mixture before separation (7×10 6 PBMCs were spiked with 20,000 tumor cells) | |
CD45 MicroBeads, humanFigure 3Enrichment of tumor cells from a mixture of PBMCs and cells of the breast cancer cell line SK-BR3 using CD45 MicroBeads. (A) Cell mixture before separation (7×106 PBMCs were spiked with 20,000 tumor cells) (B) Negative fraction with enriched breast cancer cells | CD45 MicroBeads, humanFigure 3Enrichment of tumor cells from a mixture of PBMCs and cells of the breast cancer cell line SK-BR3 using CD45 MicroBeads. (A) Cell mixture before separation (7×106 PBMCs were spiked with 20,000 tumor cells) (B) Negative fraction with enriched breast cancer cells |
Seems like you are coming from USA!
Do you want to visit our website in your country?
Copyright © 2022 Miltenyi Biotec and/or its affiliates. All rights reserved.